Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here's what's happening

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck's immunotherapy medication Keytruda, met initial goals in a late-stage trial.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。